Menu Search
Equities

Photocure ASA

PHO:OSL

Photocure ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)49.65
  • Today's Change0.10 / 0.20%
  • Shares traded50.79k
  • 1 Year change+0.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Photocure ASA grew revenues 27.35% from 393.13m to 500.66m while net income improved from a loss of 71.86m to a gain of 979.00k.
Gross margin94.47%
Net profit margin2.69%
Operating margin7.92%
Return on assets1.99%
Return on equity2.92%
Return on investment2.23%
More ▼

Cash flow in NOKView more

In 2023, Photocure ASA did not generate a significant amount of cash. However, the company earned 48.31m from its operations for a Cash Flow Margin of 9.65%. In addition the company used 594.00k on investing activities and also paid 56.28m in financing cash flows.
Cash flow per share1.59
Price/Cash flow per share31.22
Book value per share18.44
Tangible book value per share9.43
More ▼

Balance sheet in NOKView more

Photocure ASA has little financial risk as the capital structure does not rely on leverage.
Current ratio5.16
Quick ratio4.73
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in NOK

Year on year, growth in earnings per share excluding extraordinary items increased 101.36%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		141.39
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.